AMIN ROSTAMI-HODJEGAN, PhD, FCP, FAAPS, FJSSX, FBPS Professor of Systems Pharmacology and Director of Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, UK & SVP of R&D, Chief Scientific Officer (CSO), Certara, Princeton, USA

The Institute of Scientific Information (ISI, Clativate) listed Amin as one of the world’s most highly cited researchers (under ‘Pharmacology & Toxicology’) in 2017. Amin is also at 0.05% top rank of the Highly Cited Researchers Lis of 2021 published by Elsevier for ‘Pharmacology’ in October 2022. Amin has published over 300 peer reviewed highly influential scientific articles (>22,000 citations, h-index = 80). The work of Professor Rostami covers wide areas of drug development over the last 30 years, ranging from pharmaceutics (e.g. bioavailability and bioequivalence) to clinical pharmacology (e.g. mixture pharmacology of drug/metabolites), translational and systems pharmacology (e.g. quantitative proteomics of enzymes and transporter for in vitro to in vivo (IVIVE) scaling). Amin has been the winner of the OSCAR Award (Outstanding Scientific Contribution to Animal Replacement) by Hadwen Trust for Humane Research (2009); joint recipient of EUFEPS (European Federation of Pharmaceutical Sciences) Award for “New Safe Medicines Faster” Initiative (2004) and ISoP (International Society of Pharmacometrics) Award for Research Innovation (2022), and most recently, the recipient of the “European Scientific Achievement” Award of the ISSX (2023); His “Fellowship Awards” includes several scientific societies (FPS - American College of Clinical Pharmacology, FBPS - British Pharmacological Society), FAAPS – American Association of Pharmaceutical Science), and, FJSSX – Japanese Society of Study of Xenobiotics) for being a distinguished contributor and an acknowledged leader in the fields of Clinical Pharmacology, Pharmaceutics and Xenobiotics. Amin was co-founder of two spin-off companies from the University of Sheffield (Simcyp Limited and Diurnal PLC). As a leader in the field of physiologically-based pharmacokinetics (PBPK) and quantitative systems pharmacology (QSP), he is internationally recognized for his expertise in IVIVE to predict the behavior of drugs in human body and understanding the associated inter individual variabilities. He was one of the founding editors of Pharmacometrics and System Pharmacology, and serves on the Editorial Boards of several other journals. As the Senior Vice President of Research & Development (SVP) and Chief Scientific Officer at Certara, he facilitates the incorporation and integration of the latest advances in translational modelling to biosimulation platforms offered by Certara to its clients, with the aim of accelerating the development and regulatory approval of safer drug products and bringing them to the patients.